Daiichi Sankyo and AstraZeneca Report P-II trial (DESTINY-PanTumor02) Results of Enhertu (trastuzumab deruxtecan) for HER2 Expressing Advanced Solid Tumors
Shots:
- The P-II trial (DESTINY-PanTumor02) evaluating Enhertu (5.4mg/kg) in 268 patients with prior-treated LA, unresectable or metastatic HER2 expressing solid tumors not eligible for curative therapy, incl. biliary tract, bladder, cervical, endometrial, ovarian, pancreatic & rare cancers
- The trial met the pre-specified target for ORR & showed a durable response. The safety profile was consistent with that observed in other trials with no new safety signals
- The results will be presented at an upcoming medical meeting & shared with global regulatory authorities. Enhertu (5.4mg/kg) was approved in 40+ countries for unresectable or metastatic HER2+ breast cancer, based on (DESTINY-Breast03) trial results
Ref: Businesswire | Image: Daiichi Sankyo
Related Post:- AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) Receives NMPA’s Approval for HER2-Positive Metastatic Breast Cancer
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
